Slingshot members are tracking this event:

Merck’s BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 17, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Bridion, Sugammadex, Fda, Approval